期刊
REVISTA ESPANOLA DE CARDIOLOGIA
卷 74, 期 2, 页码 149-158出版社
EDICIONES DOYMA S A
DOI: 10.1016/j.recesp.2019.12.017
关键词
Cardiac amyloidosis; Amyloid light-chain amyloidosis; Transthyretin amyloidosis; Transthyretin; Prognosis; Treatment
Cardiac amyloidosis is a disease caused by amyloid fiber deposition in the myocardium, with different subtypes leading to varied presentation and outcomes. Early diagnosis and treatment improvements are crucial in reducing mortality for these patients.
Introduction and objectives . Cardiac amyloidosis (CA) is produced by amyloid fiber deposition in the myocardium. The most frequent forms are those caused by light chains (AL) and transthyretin (ATTR). Our objective was to describe the diagnosis, treatment and outcomes of CA in a specialized Spanish center. Methods: We included all patients diagnosed with CA in Hospital Universitario Puerta de Hierro Majadahonda from May 2008 to September 2018. We analyzed their clinical characteristics, outcomes, and survival. Results: We included 180 patients with CA, of whom 64 (36%) had AL (50% men; mean age, 65 +/- 11 years) and 116 had ATTR (72% men; mean age 79 +/- 11 years; 18 with hereditary ATTR). The most common presentation was heart failure in both groups (81% in AL and 45% in ATTR, P < .01). Other forms of presentation in ATTR patients were atrial arrhythmias (16%), conduction disorders (6%), and incidental finding (6%); 70 patients (40%), had a previous alternative cardiac diagnosis. Diagnosis was noninvasive in 75% of ATTR patients. Diagnostic delay was higher in ATTR (2.8 +/- 4.3 vs 0.6 +/- 0.7 years, P < .001), but mortality was greater in AL patients (48% vs 32%, P = .028). Independent predictors of mortality were AL subtype (HR, 6.16; 95%CI, 1.56-24.30; P = .01), female sex (HR, 2.35; 95%CI,1.24-4.46; P= .01), and NYHA functional class III-IV (HR, 2.07; 95%CI, 1.11-3.89; P = .02). Conclusions: CA is a clinical challenge, with wide variability in its presentation depending on the subtype, leading to diagnostic delay and high mortality. Improvements are needed in the early diagnosis and treatment of these patients. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据